Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BBP-398 + Sotorasib in KRAS G12C-Mutated Advanced Solid Tumors
NCT05480865Phase 1Terminated
- Sponsor
- BridgeBio Pharma
- Start
- Jul 2022
- Primary completion
- Aug 2024
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 1, open-label trial of BMS-986466 in solid tumor (advanced stage) and non-small cell lung cancer (NSCLC) (5 arms), sponsored by BridgeBio Pharma. Primary endpoints: Incidence and Severity of Treatment-Emergent Adverse Events at 28 days, Dose Limiting Toxicities at 28 days and 1 more. Started Jul 2022; status: terminated.
02
Drugs
BMS-986466
03
Conditions
solid tumor (advanced stage)non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05480865.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05480865.